Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058744 · ClinicalTrials.gov registry record · Phase 1
Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
A Phase 1 study of Psoriasis, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 12
- Study locations
NCT03058744: Completed Phase 1 study of Psoriasis, sponsored by Bausch Health Americas.
NCT03058744 is a Phase 1 study of Psoriasis that has completed, run by Bausch Health Americas. The registered enrollment target is 94 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (81% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03058744, a Phase 1 study of Psoriasis, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 12
- Study locations
Study Summary
Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis.
Primary Outcome
Tolerability will be evaluated through assessment of local signs and symptoms (itching, dryness, burning/stinging) on a scale of non, mild, moderate, and severe.
Conditions Studied
Interventions
- DRUG IDP-118 Lotion
- DRUG HP Monad Lotion
- DRUG Ultravate Cream
- DRUG Tazorac Cream
Study Locations (12)
California
- Valeant Site 12 - Anaheim
- Valeant Site 05 - Encino
- Valeant Site 01 - San Diego
- Valeant Site 07 - Santa Rosa
Florida
- Valeant Site 10 - Orange Park
- Valeant Site 09 - Sanford
Texas
- Valeant Site 03 - Austin
- Valeant Site 02 - Katy
Georgia
- Valeant Site 08 - Atlanta
Indiana
- Valeant Site 04 - Plainfield
New York
- Valeant Site 06 - New York
Pennsylvania
- Valeant Site 11 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
What the finished NCT03058744 record still lists
NCT03058744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which IDP-118 Lotion is the first listed.
NCT03058744 lists 12 locations in 7 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT03058744 about?
NCT03058744 is a clinical study titled "Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis". Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis.
What is the current status of trial NCT03058744?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2015-04. Estimated completion is 2017-01.
What conditions does trial NCT03058744 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03058744?
The interventions under investigation include: IDP-118 Lotion (DRUG), HP Monad Lotion (DRUG), Ultravate Cream (DRUG), Tazorac Cream (DRUG).
Who is sponsoring clinical trial NCT03058744?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03058744 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03058744's enrollment target sits among peer trials
94 60th of 125 higher than 66 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia